Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.03 | 7.07 | 7.87 | 6.20 | 8.29 | 4.02 | 6.97 | 2.69 | 2.02 | 4.30 | 3.45 | 2.79 |
| Expenses | 5.53 | 6.37 | 8.37 | 6.48 | 7.84 | 5.80 | 7.20 | 6.07 | 4.93 | 5.36 | 5.51 | 4.62 |
| Operating Profit | 0.50 | 0.70 | -0.50 | -0.28 | 0.45 | -1.78 | -0.23 | -3.38 | -2.91 | -1.06 | -2.06 | -1.83 |
| OPM % | 8.29% | 9.90% | -6.35% | -4.52% | 5.43% | -44.28% | -3.30% | -125.65% | -144.06% | -24.65% | -59.71% | -65.59% |
| Other Income | 0.07 | 0.09 | 0.24 | 0.15 | 0.29 | 0.16 | 2.14 | 0.33 | 1.53 | 0.76 | 5.59 | 0.05 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.45 | 0.45 | 0.33 | 0.43 | 0.43 | 0.43 | 0.44 | 0.44 | 0.44 | 0.44 | 0.50 | 0.45 |
| Profit before tax | 0.12 | 0.34 | -0.59 | -0.56 | 0.31 | -2.05 | 1.45 | -3.50 | -1.82 | -0.74 | 3.03 | -2.23 |
| Tax % | 0.00% | 150.00% | 83.05% | 0.00% | 0.00% | 0.00% | -18.62% | 0.00% | 0.00% | 4.05% | -0.33% | 0.00% |
| Net Profit | 0.12 | -0.16 | -1.08 | -0.56 | 0.31 | -2.05 | 1.72 | -3.49 | -1.82 | -0.77 | 3.04 | -2.23 |
| EPS in Rs | 0.10 | -0.13 | -0.87 | -0.45 | 0.25 | -1.64 | 1.38 | -2.80 | -1.46 | -0.62 | 2.44 | -1.79 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.97 | 44.04 | 53.70 | 51.79 | 43.05 | 57.42 | 69.87 | 49.37 | 27.35 | 25.48 | 12.45 | 12.56 |
| Expenses | 40.36 | 42.43 | 51.53 | 47.07 | 49.80 | 46.45 | 59.80 | 44.18 | 27.35 | 27.28 | 21.86 | 20.42 |
| Operating Profit | 2.61 | 1.61 | 2.17 | 4.72 | -6.75 | 10.97 | 10.07 | 5.19 | 0.00 | -1.80 | -9.41 | -7.86 |
| OPM % | 6.07% | 3.66% | 4.04% | 9.11% | -15.68% | 19.10% | 14.41% | 10.51% | 0.00% | -7.06% | -75.58% | -62.58% |
| Other Income | 0.68 | 2.02 | 1.07 | 2.73 | 2.86 | 1.77 | 1.95 | 1.49 | 0.48 | 2.73 | 8.21 | 7.93 |
| Interest | 0.06 | 0.10 | 0.10 | 0.13 | 0.12 | 0.10 | 0.11 | 0.13 | 0.04 | 0.05 | 0.02 | 0.00 |
| Depreciation | 1.80 | 1.81 | 1.79 | 1.82 | 1.83 | 1.52 | 1.81 | 1.74 | 1.69 | 1.72 | 1.81 | 1.83 |
| Profit before tax | 1.43 | 1.72 | 1.35 | 5.50 | -5.84 | 11.12 | 10.10 | 4.81 | -1.25 | -0.84 | -3.03 | -1.76 |
| Tax % | 39.16% | 20.35% | 14.81% | 2.18% | 0.17% | -0.09% | 0.10% | 63.62% | 80.00% | -32.14% | 0.66% | |
| Net Profit | 0.86 | 1.37 | 1.15 | 5.39 | -5.85 | 11.13 | 10.08 | 1.76 | -2.24 | -0.57 | -3.04 | -1.78 |
| EPS in Rs | 0.69 | 1.10 | 0.92 | 4.32 | -4.69 | 8.93 | 8.08 | 1.41 | -1.80 | -0.46 | -2.44 | -1.43 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -12% | -26% | -37% | -43% | ||
| Compounded Profit Growth | % | % | % | 49% | ||
| Stock Price CAGR | 3% | -9% | -14% | -31% | ||
| Return on Equity | 1% | -1% | -4% | -9% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Reserves | 68.94 | 69.80 | 76.62 | 77.75 | 83.13 | 78.48 | 92.24 | 103.79 | 106.10 | 108.51 | 108.81 | 99.14 |
| Borrowings | 0.81 | 0.08 | 0.09 | 0.17 | 0.12 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 7.00 | 10.68 | 8.19 | 10.52 | 10.89 | 4.20 | 10.11 | 14.09 | 7.42 | 6.31 | 4.14 | 3.85 |
| Total Liabilities | 89.22 | 93.03 | 97.37 | 100.91 | 106.61 | 95.21 | 114.82 | 130.35 | 125.99 | 127.29 | 125.42 | 115.46 |
| Fixed Assets | 58.05 | 56.41 | 62.14 | 61.03 | 59.80 | 57.30 | 58.12 | 59.31 | 58.91 | 58.65 | 57.18 | 56.29 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.97 | 0.54 | 0.24 | 0.00 | 0.00 | 0.08 | 0.00 |
| Investments | 5.43 | 6.74 | 7.83 | 11.18 | 16.35 | 21.97 | 29.41 | 30.67 | 32.07 | 38.38 | 43.04 | 34.82 |
| Other Assets | 25.74 | 29.88 | 27.40 | 28.70 | 30.46 | 14.97 | 26.75 | 40.13 | 35.01 | 30.26 | 25.12 | 24.35 |
| Total Assets | 89.22 | 93.03 | 97.37 | 100.91 | 106.61 | 95.21 | 114.82 | 130.35 | 125.99 | 127.29 | 125.42 | 115.46 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 7.05 | 2.59 | 4.02 | 4.20 | 5.96 | 4.63 | 15.32 | 7.02 | -6.08 | 6.94 | 5.07 | -7.02 |
| Cash from Investing Activity | -6.97 | -1.47 | 2.57 | -4.09 | -5.75 | -5.80 | -9.70 | -4.08 | -2.56 | -7.73 | -4.98 | 7.11 |
| Cash from Financing Activity | 0.00 | -0.73 | -5.76 | 0.08 | -0.05 | -0.06 | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash Flow | 0.08 | 0.39 | 0.83 | 0.20 | 0.16 | -1.23 | 5.56 | 2.95 | -8.64 | -0.79 | 0.09 | 0.09 |
| Free Cash Flow | 6.58 | 2.43 | 9.11 | 3.51 | 5.37 | 3.38 | 13.06 | 4.23 | -7.24 | 6.59 | 4.74 | -7.87 |
| CFO/OP | -9,750% | 120% | 270% | 202% | 128% | -69% | 140% | 70% | -58% | -267% | 74% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87.33 | 82.48 | 74.09 | 88.57 | 90.56 | 37.39 | 40.62 | 52.61 | 62.55 | 144.40 | 125.92 | 202.88 |
| Inventory Days | 265.71 | 257.13 | 230.21 | 148.16 | 163.52 | 75.29 | 83.45 | 156.60 | 121.72 | 243.05 | 120.79 | 209.59 |
| Days Payable | 66.33 | 101.86 | 75.75 | 90.99 | 96.26 | 26.94 | 76.61 | 154.35 | 48.72 | 77.49 | 59.64 | 34.22 |
| Cash Conversion Cycle | 286.71 | 237.75 | 228.56 | 145.73 | 157.82 | 85.74 | 47.46 | 54.85 | 135.55 | 309.96 | 187.06 | 378.25 |
| Working Capital Days | 184.07 | 154.26 | 147.11 | 113.17 | 127.42 | 84.70 | 65.41 | 87.66 | 200.50 | 324.16 | 304.12 | 598.07 |
| ROCE % | -0.69% | 1.81% | 1.48% | 1.56% | 5.77% | -6.58% | 11.59% | 8.78% | 3.70% | -1.17% | -2.12% | -9.19% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.13% | 50.13% | 50.13% | 50.13% | 50.42% | 50.61% | 50.76% | 50.76% | 50.76% | 50.76% | 51.36% | 51.44% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.02% | 0.02% | 0.02% |
| Public | 49.84% | 49.85% | 49.84% | 49.83% | 49.54% | 49.35% | 49.21% | 49.21% | 49.19% | 49.21% | 48.61% | 48.54% |
| No. of Shareholders | 13,790 | 13,226 | 12,356 | 11,738 | 11,255 | 11,176 | 11,033 | 10,851 | 10,692 | 10,493 | 10,349 | 10,209 |
Fundamentals
Market Cap₹ 33.6 Cr.
Current Price₹ 27.0
Book Value₹ 89.5
ROCE-9.19 %
ROE-9.21 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-43%
Compounded Profit Growth (TTM)49%
Consolidated figures.
Valuation
Market capRs 32 Cr
Enterprise valueRs 32 Cr
Price to book0.29x
Price to sales2.59x
EV / EBITDA355.38x
EV / sales2.55x
Earnings yield-5.48%
P/B, 3-year average0.38x
P/E, 5-year average15.45x
P/B, 5-year average0.41x
Profitability
Operating margin (excl. other income)-75.58%
Operating margin (incl. other income)-9.64%
EBITDA margin0.72%
Pre-tax margin-14.01%
Net profit margin-14.17%
Net margin, latest quarter-79.93%
ROE-2.61%
ROCE-2.58%
ROA-2.52%
ROE, 3-year average-1.65%
ROCE, 3-year average-1.42%
ROA, 3-year average-1.58%
ROE, 5-year average1.13%
ROCE, 5-year average1.84%
ROA, 5-year average0.97%
ROIC (approx.)-1.58%
Tax rate-0.66%
Other income / net worth7.36%
Growth
Sales growth (latest year)-51.14%
Sales CAGR, 3 years-36.82%
Sales CAGR, 5 years-26.34%
Sales growth QoQ-19.13%
Profit growth QoQ-173.36%
Sales growth YoY (latest quarter)3.72%
Per share
EPS (TTM)Rs -1.43
EPS (latest year)Rs -2.44
EPS (latest quarter)Rs -1.79
EPS, 3-year averageRs -1.56
EPS, 5-year averageRs 0.96
Book value per shareRs 89.50
Sales per shareRs 10.07
Cash flow per shareRs -5.63
Free cash flow per shareRs -6.31
Efficiency
Asset turnover0.11x
Fixed asset turnover0.22x
Inventory turnover2.73x
Inventory days134 days
Debtor days203 days
Debtors turnover1.80x
Creditor days34 days
Cash conversion cycle378 days
Working capital days598 days
Leverage
Cash and bankRs 0 Cr
Net debtRs -0 Cr
Net debt / EBITDA-5.56x
Interest coverage-87.00x
Owners' fund to total sources96.67%
Cash flow
Cash from Operating Activity (latest year)Rs -7 Cr
Cash from Investing Activity (latest year)Rs 7 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -8 Cr
Cash from ops / profit, 5 years0.99x
Statement figures
Net sales (TTM)Rs 13 Cr
Net sales (latest year)Rs 12 Cr
Sales (latest quarter)Rs 3 Cr
Operating profit excl. other income (latest year)Rs -9 Cr
Operating profit (latest quarter)Rs -2 Cr
Other income (TTM)Rs 8 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs -2 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -2 Cr
Net profit (latest year)Rs -3 Cr
Net profit (latest quarter)Rs -2 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 8 Cr
Total expenditure (latest year)Rs 22 Cr
Total income (latest year)Rs 21 Cr
Share capitalRs 12 Cr
ReservesRs 99 Cr
Shareholders' fundsRs 112 Cr
Total assetsRs 115 Cr
Net blockRs 56 Cr
InvestmentsRs 35 Cr
ReceivablesRs 7 Cr
InventoryRs 3 Cr
Other liabilitiesRs 4 Cr
Shares outstanding (crore)1.25
Ownership
Promoter holding51.44% (+0.68 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 0.29 is at the 27th percentile (median 0.39).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | MEDICAPQ | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +4.2% | -2.8% | +7.0 pts |
| 1 month | -3.5% | -6.8% | +3.3 pts |
| 3 years | -34.9% | +14.2% | -49.1 pts |
| 5 years | -37.8% | +27.9% | -65.7 pts |
Red flags
F-score 2 of 8| explain | Receivables outrunning sales Receivables grew -21% vs sales -51% in 2026 |
| look | Inventory outrunning sales Inventory grew -8% vs sales -51% in 2026 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹3 Cr +3.7% vs Jun 2025.
Net loss ₹2 Cr.
Against our estimate for Jun 2026: sales +32.6%, profit -96.2% miss. Our estimate for Sep 2026: sales Rs 2 Cr, profit Rs -1 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of Medi Caps Ltd?
Medi Caps Ltd (MEDICAPQ) has a market capitalisation of Rs 33.6 Cr. at the 2026-10-01 close.
What were Medi Caps Ltd's latest quarterly results?
In the Jun 2026 quarter, Medi Caps Ltd sales was Rs 3 Cr (+3.7% vs Jun 2025) with a net loss of Rs 2 Cr.
What is the 52-week high and low of Medi Caps Ltd?
The 52-week high is Rs 36.80 and the 52-week low is Rs 20.33.